D.A. Davidson & Co. Intellia Therapeutics, Inc. Transaction History
D.A. Davidson & Co.
- $12.1 Billion
- Q4 2024
A detailed history of D.A. Davidson & Co. transactions in Intellia Therapeutics, Inc. stock. As of the latest transaction made, D.A. Davidson & Co. holds 14,770 shares of NTLA stock, worth $158,039. This represents 0.0% of its overall portfolio holdings.
Number of Shares
14,770
Previous 16,250
9.11%
Holding current value
$158,039
Previous $333,000
48.35%
% of portfolio
0.0%
Previous 0.0%
Shares
8 transactions
Others Institutions Holding NTLA
# of Institutions
336Shares Held
91MCall Options Held
1MPut Options Held
728K-
Cathie Wood Ark Investment Management LLC | St. Petersburg, Fl12.5MShares$134 Million1.28% of portfolio
-
Vanguard Group Inc Valley Forge, PA10.2MShares$109 Million0.0% of portfolio
-
Black Rock Inc. New York, NY9.6MShares$103 Million0.0% of portfolio
-
State Street Corp Boston, MA5.21MShares$55.7 Million0.0% of portfolio
-
Morgan Stanley New York, NY3.81MShares$40.8 Million0.0% of portfolio
About Intellia Therapeutics, Inc.
- Ticker NTLA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 76,011,800
- Market Cap $813M
- Description
- Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemoph...